Opaleye Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Opaleye Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-292,000	Closed	-$17.5M	–	57
2019 Q4	$17.5M	Buy	292,000 +7,000	+2%	+$263K	3.43%	10
2019 Q3	$8.01M	Buy	285,000 +5,000	+2%	+$171K	2.9%	13
2019 Q2	$10.6M	Hold	280,000	–	–	3.23%	11
2019 Q1	$10.9M	Buy	280,000 +30,000	+12%	+$860K	3.03%	9
2018 Q4	$5.33M	Buy	250,000 +25,000	+11%	+$645K	1.99%	19
2018 Q3	$8.91M	Buy	225,000 +35,000	+18%	+$1.3M	2.27%	11
2018 Q2	$7.26M	Hold	190,000	–	–	1.88%	18
2018 Q1	$5.71M	Sell	190,000 -20,000	-10%	-$677K	1.63%	19
2017 Q4	$6.65M	Buy	210,000 +30,000	+17%	+$824K	2.13%	14
2017 Q3	$5.04M	Buy	180,000 +30,000	+20%	+$651K	1.78%	19
2017 Q2	$2.87M	Buy	+150,000	New	+$2.4M	1.2%	23

Opaleye Management's BOLD Position: Q1 2020 in Review

Opaleye Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 292,000 shares — an estimated $17.5M sold.

Opaleye Management first reported a position in BOLD in Q2 2017 and held it in 11 quarters. The position peaked at $17.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Opaleye Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Opaleye Management sold 292,000 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $17.5M.
Opaleye Management first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 11 quarters.
Opaleye Management's Audentes Therapeutics, Inc position peaked at $17.5M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.